Harrow Health 8625 Stock Fundamentals
| HROWL Stock | USD 25.43 0.08 0.32% |
Harrow Health 8625 fundamentals help investors to digest information that contributes to Harrow Health's financial success or failures. It also enables traders to predict the movement of Harrow Stock. The fundamental analysis module provides a way to measure Harrow Health's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Harrow Health stock.
At this time, Harrow Health's EBITDA is quite stable compared to the past year. Total Operating Expenses is expected to rise to about 94.5 M this year, although the value of EBIT will most likely fall to (2.7 M). Harrow | Select Account or Indicator |
Harrow Health 8625 Company Revenue Analysis
Harrow Health's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Harrow Health Revenue | 130.19 M |
Most of Harrow Health's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Harrow Health 8625 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Harrow Revenue Historical Pattern
Today, most investors in Harrow Health Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Harrow Health's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Harrow Health revenue as a starting point in their analysis.
Harrow Health Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Harrow Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Harrow Health 8625 reported 130.19 M of revenue. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is notably lower than that of the firm.
Harrow Health 8625 Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Harrow Health's current stock value. Our valuation model uses many indicators to compare Harrow Health value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Harrow Health competition to find correlations between indicators driving Harrow Health's intrinsic value. More Info.Harrow Health 8625 is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in number of shares shorted category among its peers making about 1,599 of Number Of Shares Shorted per Return On Equity. At this time, Harrow Health's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Harrow Health by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Harrow Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Harrow Health's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Harrow Health could also be used in its relative valuation, which is a method of valuing Harrow Health by comparing valuation metrics of similar companies.Harrow Health is currently under evaluation in revenue category among its peers.
Harrow Health Current Valuation Drivers
We derive many important indicators used in calculating different scores of Harrow Health from analyzing Harrow Health's financial statements. These drivers represent accounts that assess Harrow Health's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Harrow Health's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 197.0M | 177.6M | 231.2M | 405.3M | 365.3M | 383.6M | |
| Enterprise Value | 213.3M | 197.1M | 267.0M | 413.2M | 481.7M | 505.8M |
Harrow Health ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Harrow Health's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Harrow Health's managers, analysts, and investors.Environmental | Governance | Social |
Harrow Fundamentals
| Return On Equity | 0.45 | ||||
| Number Of Shares Shorted | 717 | ||||
| Revenue | 130.19 M | ||||
| EBITDA | 9.72 M | ||||
| Net Income | (24.41 M) | ||||
| Total Debt | 190.5 M | ||||
| Cash Flow From Operations | 3.84 M | ||||
| Market Capitalization | 247.48 M | ||||
| Total Asset | 311.75 M | ||||
| Retained Earnings | (133.9 M) | ||||
| Net Asset | 311.75 M |
About Harrow Health Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Harrow Health 8625's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harrow Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harrow Health 8625 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 75 K | 71.3 K | |
| Total Revenue | 130.2 M | 136.7 M | |
| Cost Of Revenue | 39.6 M | 41.6 M | |
| Stock Based Compensation To Revenue | 0.12 | 0.11 | |
| Sales General And Administrative To Revenue | 0.77 | 0.73 | |
| Research And Ddevelopement To Revenue | 0.05 | 0.05 | |
| Capex To Revenue | 1.17 | 1.23 | |
| Revenue Per Share | 3.99 | 4.19 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Harrow Health Piotroski F Score and Harrow Health Altman Z Score analysis. For more information on how to buy Harrow Stock please use our How to buy in Harrow Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harrow Health. If investors know Harrow will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harrow Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Equity 0.4484 |
The market value of Harrow Health 8625 is measured differently than its book value, which is the value of Harrow that is recorded on the company's balance sheet. Investors also form their own opinion of Harrow Health's value that differs from its market value or its book value, called intrinsic value, which is Harrow Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harrow Health's market value can be influenced by many factors that don't directly affect Harrow Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harrow Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harrow Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harrow Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.